Outset Medical Inc. reported third-quarter 2025 net revenue of $29.4 million, an increase of 3.0% from the same period last year, driven by an 8.0% rise in Tablo console revenue. Recurring revenue from Tablo consumables and services reached $21.1 million, showing a slight increase from the prior year period. Gross margin was 39.4%, with a non-GAAP gross margin of 39.9%, up 3.5 percentage points year-over-year. Operating expenses declined nearly 20% compared to the third quarter of 2024, and the company used less than $6.0 million in cash during the quarter, ending with approximately $182 million in cash and short-term investments. Outset Medical revised its 2025 revenue outlook to $115-$120 million, down from a previous range of $122-$126 million, while maintaining its non-GAAP gross margin guidance in the high-30% range. The company expects to use less than $50 million in cash for 2025, compared to over $100 million used in 2024.